{"success":true,"data":{"pressRelease":{"id":"109478","rtpr_id":"nBw3v1jFca","ticker":"GCTK","exchange":"NASDAQ","all_tickers":["GCTK"],"title":"Glucotrack Announces $5.5 Million Financing","author":"Business Wire","published_at":"2026-08-05T12:30:00.594Z","article_body":"Glucotrack Announces $5.5 Million Financing\n\nIncludes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium\nto the market, and $3.5 Million Follow-On Investment from Institutional\nInvestors\n\nGlucotrack, Inc. (NASDAQ: GCTK) (\"Glucotrack\" or the \"Company\") today\nannounced definitive agreements for approximately $5.5 million in financing\nfrom participating institutional investors, including a $2.0 million equity\nfinancing priced at $0.75 per unit and a $3.5 million follow-on investment in\nthe form of convertible debt.\n\nThe equity financing consists of units priced at $0.75 per unit, with each\nunit comprised of one share of common stock (or equivalent) and one five-year\nwarrant with an exercise price of $1.50 per share.\n\n\"We believe one of the strongest signals investors can send is choosing to\nincrease their alignment with common shareholders,\" said Erik Emerson, Chief\nExecutive Officer of Glucotrack. \"This financing strengthens our balance\nsheet, provides additional growth capital, and reflects confidence in our\nlong-term strategy. We believe it positions us well as we continue executing\nacross our portfolio of opportunities.\"\n\nE.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics™,\na subsidiary of Glucotrack, in conjunction with the transaction.\n\nAbout Glucotrack, Inc.\n\nGlucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary\nGlucotrack Technologies, Inc., is also focused on the design, development, and\ncommercialization of novel technologies for people with diabetes, including a\nlong-term implantable continuous blood glucose monitoring system. The\nGlucotrack CBGM is an Investigational Device and is limited by federal (or\nUnited States) law to investigational use. For more information, please visit\nwww.glucotrack.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.glucotrack.com___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDozYmFmZDQ1YzkyNWFlMDQxNzkxYzFlNjU1ODliMjljNjo3OjVjYjk6ZjgxYjBhMzhiYTk4YzY2YjIzMzkyYmQzZDQ2MDJlYzUwMzg2NzJiZDQ5MWFlZjVlN2QwZjllNmU3ZDViYzdiOTpwOkY6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.glucotrack.com&index=1&md5=e455600e29363afcbdc22c89b164fca4)\n.\n\nAbout Lōkahi Therapeutics™\n\nLōkahi Therapeutics is a capital-efficient biopharmaceutical platform company\nfocused on identifying, evaluating, acquiring, and advancing overlooked\ntherapeutic assets. Through its ai² platform and ai² Futures Lab execution\nmodel, Lōkahi integrates cross-functional expertise and disciplined\ndecision-making to drive strategic development and long-term value creation.\nFor more information, please visit www.lokahithera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.globenewswire.com%2FTracker%3Fdata%3DQLuJnTx3A6Xswjosz5FqUzt9KWLpAhJ4x44o8hd2QYRAlDjymNnrxGab7L3KQ7Y8qX5mpnxvgEGzPgtAYjEkoxBYlC3C_OP9vlyG2oXEwmcUBygFB0dd9pPv78GY8GB-pIIYYAEzi8qRTq8YhL-ksTEC2GXVqxwTSiDPO9GpClDTf-I-niqYcpEYGP2fVF_t0ofg0i9UdvE_-NxSUj4stC4Y2OVOsDC1AENTEigrlgqe3JbBJKIEkes6BepKGVCB4elRMMLlDCA0ggpy6LQ0aexduHRp7MXWDK001V5Ow8w37eJ35Mr-ZrNg3HzQOh3t8tZ9fy3Vs9vrw72KG9YT9D99Hl6GJa9CNkONOVatdsScGvIUOJu9Q2k0pl2Wb0EjBgJpEyzm6GuLAO_W_I4lLeAjcSPYgYX2SVnrdvULksB3Lcfq-QDr23aoa5KfGUbwcD5bJn8eSuYtGXl8U0IPIg%3D%3D___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo0NWE0YmI1ZDI5YjA5M2UwYWM1ZDJkYjhlNTk0MGMwNzo3OjY0YTk6ODg0Yzg4ODkyNGFlN2JhMGZiNTA2NWJlODUzYzUxNzRlZDllN2FkMzM0MGFjNTk5OTQ0Y2Y3YTI5NzkzM2ExNDpwOlQ6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.lokahithera.com&index=2&md5=e7459769d45e8f2a4161d32dcc5c73f7)\n. For more information on the ai² Futures Lab program, please visit\nwww.ai2futureslab.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.ai2futureslab.com___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo0NWE0YmI1ZDI5YjA5M2UwYWM1ZDJkYjhlNTk0MGMwNzo3Ojk3NzE6MWNiNGMxOTc3MWMzMDRiNDVlNWQ0NDc1OGFlODJkNThlZmQ3NDQwY2QwYjczNWY1MTExYzI3OGY5ZDQ5ZjA5ODpwOlQ6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.ai2futureslab.com&index=3&md5=3e711f11db1e4e97f5572099adcbf200)\n.\n\nAbout E.F. Hutton & Co.\n\nE.F. Hutton & Co. is a full-service investment bank and broker-dealer\nheadquartered in New York City, serving corporations, financial sponsors, and\ninstitutional investors across the U.S., Asia, Europe, the UAE, and Latin\nAmerica. We provide a comprehensive range of investment banking and capital\nmarkets services across our specialized divisions, delivering integrated\nsolutions at every stage of the capital lifecycle. For more information,\nplease visit www.efhutton.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.efhutton.com&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.efhutton.com&index=4&md5=57832d09796b8b002367a32db4c1b38c)\n.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements contained in\nthis news release that are not statements of historical fact may be deemed to\nbe forward-looking statements. Without limiting the generality of the\nforegoing, words such as \"anticipate\", \"believe\", \"expect\", \"plan,\" and \"will\"\nare intended to identify forward-looking statements. Such forward-looking\nstatements are based on the beliefs of management, as well as assumptions made\nby, and information currently available to, management. These statements\nrelate only to events as of the date on which the statements are made, and\nGlucotrack undertakes no obligation to publicly update any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise, except as required by law. All of the forward-looking statements\nmade in this press release are qualified by these cautionary statements, and\nthere can be no assurance that the actual results anticipated by Glucotrack\nwill be realized or, even if substantially realized, that they will have the\nexpected consequences to or effects on us or our business or operations.\nReaders are cautioned that certain important factors may affect Glucotrack's\nactual results and could cause such results to differ materially from any\nforward-looking statements that may be made in this news release. Factors that\nmay affect Glucotrack's results include, but are not limited to, the ability\nof Glucotrack to raise additional capital to finance its operations (whether\nthrough public or private equity offerings, debt financings, strategic\ncollaborations or otherwise); risks relating to merger integration; risks\nrelating to the receipt (and timing) of regulatory approvals (including U.S.\nFood and Drug Administration approval); risks relating to enrollment of\npatients in, and the conduct of, clinical trials; risks relating to\nGlucotrack's future distribution agreements; risks relating to its ability to\nhire and retain qualified personnel; and the additional risk factors described\nin Glucotrack's filings with the U.S. Securities and Exchange Commission (the\n\"SEC\"), including its Annual Report on Form 10-K for the year ended December\n31, 2025 as filed with the SEC on March 30, 2026.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260805289606/en/\n(https://www.businesswire.com/news/home/20260805289606/en/)\n\nGlucotrack \n\nGlucotrackPR@icrinc.com (mailto:GlucotrackPR@icrinc.com)\n\nLōkahi Therapeutics™ \n\nir@lokahithera.com (mailto:ir@lokahithera.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3v1jFca","title":"Glucotrack Announces $5.5 Million Financing","author":"Business Wire","ticker":"GCTK","created":"2026-08-05T12:30:00.594Z","tickers":["GCTK"],"exchange":"NASDAQ","article_body":"Glucotrack Announces $5.5 Million Financing\n\nIncludes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium\nto the market, and $3.5 Million Follow-On Investment from Institutional\nInvestors\n\nGlucotrack, Inc. (NASDAQ: GCTK) (\"Glucotrack\" or the \"Company\") today\nannounced definitive agreements for approximately $5.5 million in financing\nfrom participating institutional investors, including a $2.0 million equity\nfinancing priced at $0.75 per unit and a $3.5 million follow-on investment in\nthe form of convertible debt.\n\nThe equity financing consists of units priced at $0.75 per unit, with each\nunit comprised of one share of common stock (or equivalent) and one five-year\nwarrant with an exercise price of $1.50 per share.\n\n\"We believe one of the strongest signals investors can send is choosing to\nincrease their alignment with common shareholders,\" said Erik Emerson, Chief\nExecutive Officer of Glucotrack. \"This financing strengthens our balance\nsheet, provides additional growth capital, and reflects confidence in our\nlong-term strategy. We believe it positions us well as we continue executing\nacross our portfolio of opportunities.\"\n\nE.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics™,\na subsidiary of Glucotrack, in conjunction with the transaction.\n\nAbout Glucotrack, Inc.\n\nGlucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary\nGlucotrack Technologies, Inc., is also focused on the design, development, and\ncommercialization of novel technologies for people with diabetes, including a\nlong-term implantable continuous blood glucose monitoring system. The\nGlucotrack CBGM is an Investigational Device and is limited by federal (or\nUnited States) law to investigational use. For more information, please visit\nwww.glucotrack.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.glucotrack.com___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDozYmFmZDQ1YzkyNWFlMDQxNzkxYzFlNjU1ODliMjljNjo3OjVjYjk6ZjgxYjBhMzhiYTk4YzY2YjIzMzkyYmQzZDQ2MDJlYzUwMzg2NzJiZDQ5MWFlZjVlN2QwZjllNmU3ZDViYzdiOTpwOkY6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.glucotrack.com&index=1&md5=e455600e29363afcbdc22c89b164fca4)\n.\n\nAbout Lōkahi Therapeutics™\n\nLōkahi Therapeutics is a capital-efficient biopharmaceutical platform company\nfocused on identifying, evaluating, acquiring, and advancing overlooked\ntherapeutic assets. Through its ai² platform and ai² Futures Lab execution\nmodel, Lōkahi integrates cross-functional expertise and disciplined\ndecision-making to drive strategic development and long-term value creation.\nFor more information, please visit www.lokahithera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.globenewswire.com%2FTracker%3Fdata%3DQLuJnTx3A6Xswjosz5FqUzt9KWLpAhJ4x44o8hd2QYRAlDjymNnrxGab7L3KQ7Y8qX5mpnxvgEGzPgtAYjEkoxBYlC3C_OP9vlyG2oXEwmcUBygFB0dd9pPv78GY8GB-pIIYYAEzi8qRTq8YhL-ksTEC2GXVqxwTSiDPO9GpClDTf-I-niqYcpEYGP2fVF_t0ofg0i9UdvE_-NxSUj4stC4Y2OVOsDC1AENTEigrlgqe3JbBJKIEkes6BepKGVCB4elRMMLlDCA0ggpy6LQ0aexduHRp7MXWDK001V5Ow8w37eJ35Mr-ZrNg3HzQOh3t8tZ9fy3Vs9vrw72KG9YT9D99Hl6GJa9CNkONOVatdsScGvIUOJu9Q2k0pl2Wb0EjBgJpEyzm6GuLAO_W_I4lLeAjcSPYgYX2SVnrdvULksB3Lcfq-QDr23aoa5KfGUbwcD5bJn8eSuYtGXl8U0IPIg%3D%3D___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo0NWE0YmI1ZDI5YjA5M2UwYWM1ZDJkYjhlNTk0MGMwNzo3OjY0YTk6ODg0Yzg4ODkyNGFlN2JhMGZiNTA2NWJlODUzYzUxNzRlZDllN2FkMzM0MGFjNTk5OTQ0Y2Y3YTI5NzkzM2ExNDpwOlQ6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.lokahithera.com&index=2&md5=e7459769d45e8f2a4161d32dcc5c73f7)\n. For more information on the ai² Futures Lab program, please visit\nwww.ai2futureslab.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.ai2futureslab.com___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo0NWE0YmI1ZDI5YjA5M2UwYWM1ZDJkYjhlNTk0MGMwNzo3Ojk3NzE6MWNiNGMxOTc3MWMzMDRiNDVlNWQ0NDc1OGFlODJkNThlZmQ3NDQwY2QwYjczNWY1MTExYzI3OGY5ZDQ5ZjA5ODpwOlQ6Rg&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.ai2futureslab.com&index=3&md5=3e711f11db1e4e97f5572099adcbf200)\n.\n\nAbout E.F. Hutton & Co.\n\nE.F. Hutton & Co. is a full-service investment bank and broker-dealer\nheadquartered in New York City, serving corporations, financial sponsors, and\ninstitutional investors across the U.S., Asia, Europe, the UAE, and Latin\nAmerica. We provide a comprehensive range of investment banking and capital\nmarkets services across our specialized divisions, delivering integrated\nsolutions at every stage of the capital lifecycle. For more information,\nplease visit www.efhutton.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.efhutton.com&esheet=54583738&newsitemid=20260805289606&lan=en-US&anchor=www.efhutton.com&index=4&md5=57832d09796b8b002367a32db4c1b38c)\n.\n\nForward-Looking Statements\n\nThis news release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements contained in\nthis news release that are not statements of historical fact may be deemed to\nbe forward-looking statements. Without limiting the generality of the\nforegoing, words such as \"anticipate\", \"believe\", \"expect\", \"plan,\" and \"will\"\nare intended to identify forward-looking statements. Such forward-looking\nstatements are based on the beliefs of management, as well as assumptions made\nby, and information currently available to, management. These statements\nrelate only to events as of the date on which the statements are made, and\nGlucotrack undertakes no obligation to publicly update any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise, except as required by law. All of the forward-looking statements\nmade in this press release are qualified by these cautionary statements, and\nthere can be no assurance that the actual results anticipated by Glucotrack\nwill be realized or, even if substantially realized, that they will have the\nexpected consequences to or effects on us or our business or operations.\nReaders are cautioned that certain important factors may affect Glucotrack's\nactual results and could cause such results to differ materially from any\nforward-looking statements that may be made in this news release. Factors that\nmay affect Glucotrack's results include, but are not limited to, the ability\nof Glucotrack to raise additional capital to finance its operations (whether\nthrough public or private equity offerings, debt financings, strategic\ncollaborations or otherwise); risks relating to merger integration; risks\nrelating to the receipt (and timing) of regulatory approvals (including U.S.\nFood and Drug Administration approval); risks relating to enrollment of\npatients in, and the conduct of, clinical trials; risks relating to\nGlucotrack's future distribution agreements; risks relating to its ability to\nhire and retain qualified personnel; and the additional risk factors described\nin Glucotrack's filings with the U.S. Securities and Exchange Commission (the\n\"SEC\"), including its Annual Report on Form 10-K for the year ended December\n31, 2025 as filed with the SEC on March 30, 2026.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260805289606/en/\n(https://www.businesswire.com/news/home/20260805289606/en/)\n\nGlucotrack \n\nGlucotrackPR@icrinc.com (mailto:GlucotrackPR@icrinc.com)\n\nLōkahi Therapeutics™ \n\nir@lokahithera.com (mailto:ir@lokahithera.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-05T12:30:00.93490925Z","server_sent_at_ms":1785933000934},"received_at":"2026-08-05T12:30:00.985Z","source_url":"https://www.businesswire.com/news/home/20260805289606/en/"},"analysis":{"id":"98484","press_release_id":"109478","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Future dilution risk associated with warrants and convertible debt","Use of proceeds limited to general growth capital and balance sheet strength"],"eventType":"offering","narrative":"Glucotrack secured approximately $5.5 million in gross proceeds from institutional investors, split between a $2.0 million equity financing and a $3.5 million follow-on investment in convertible debt.\n\nThe equity units were priced at $0.75 per share, a premium to the market, and include five-year warrants exercisable at $1.50 per share.\n\nManagement stated the capital strengthens the balance sheet and provides growth funding, highlighting the premium pricing as a strong signal of investor alignment.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small-cap financing priced at a premium signals institutional support."},"keyFigures":{"dealValueUsd":5500000,"offeringPrice":0.75,"customDimensions":{"warrant_term_years":5,"convertible_debt_usd":3500000,"equity_financing_usd":2000000,"warrant_exercise_price":1.5}},"quotedText":"This financing strengthens our balance sheet, provides additional growth capital, and reflects confidence in our long-term strategy.","namedEntities":{"people":[{"name":"Erik Emerson","role":"Chief Executive Officer"}],"products":["Glucotrack CBGM","ai² platform","ai² Futures Lab execution model"],"companies":[{"name":"Glucotrack, Inc.","ticker":"GCTK"},{"name":"Lōkahi Therapeutics™","relationship":"subsidiary"},{"name":"E.F. Hutton & Co.","relationship":"exclusive advisor"}],"dollarAmounts":[{"amount":"$5.5 million","context":"total financing"},{"amount":"$2.0 million","context":"equity financing"},{"amount":"$0.75","context":"price per unit"},{"amount":"$3.5 million","context":"follow-on investment / convertible debt"},{"amount":"$1.50","context":"warrant exercise price"}]},"materialImpact":{"score":3,"reasoning":"The company secured $5.5 million in growth capital through a mixed equity and debt financing. While the issuance of warrants and convertible debt introduces dilution risk, the equity component was priced at a premium to the market, a signal of institutional confidence that mitigates typical dilutive bearishness."},"tickerRelevance":{"others":[],"primary":"GCTK"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small_cap_financing","pricingSignal":"premium_pricing"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":3,"narrative":"Glucotrack secured approximately $5.5 million in gross proceeds from institutional investors, split between a $2.0 million equity financing and a $3.5 million follow-on investment in convertible debt.\n\nThe equity units were priced at $0.75 per share, a premium to the market, and include five-year warrants exercisable at $1.50 per share.\n\nManagement stated the capital strengthens the balance sheet and provides growth funding, highlighting the premium pricing as a strong signal of investor alignment.","key_figures":{"dealValueUsd":5500000,"offeringPrice":0.75,"customDimensions":{"warrant_term_years":5,"convertible_debt_usd":3500000,"equity_financing_usd":2000000,"warrant_exercise_price":1.5}},"named_entities":{"people":[{"name":"Erik Emerson","role":"Chief Executive Officer"}],"products":["Glucotrack CBGM","ai² platform","ai² Futures Lab execution model"],"companies":[{"name":"Glucotrack, Inc.","ticker":"GCTK"},{"name":"Lōkahi Therapeutics™","relationship":"subsidiary"},{"name":"E.F. Hutton & Co.","relationship":"exclusive advisor"}],"dollarAmounts":[{"amount":"$5.5 million","context":"total financing"},{"amount":"$2.0 million","context":"equity financing"},{"amount":"$0.75","context":"price per unit"},{"amount":"$3.5 million","context":"follow-on investment / convertible debt"},{"amount":"$1.50","context":"warrant exercise price"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T17:39:47.143Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small_cap_financing","pricingSignal":"premium_pricing"}},"durationMs":139041,"modelName":"glm-4.7"}}